

# Emilio Russo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3007930/publications.pdf>

Version: 2024-02-01

250  
papers

7,890  
citations

47006

47  
h-index

91884

69  
g-index

255  
all docs

255  
docs citations

255  
times ranked

9943  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antidepressant Drugs for Seizures and Epilepsy: Where do we Stand?. <i>Current Neuropharmacology</i> , 2023, 21, 1691-1713.	2.9	4
2	Autosomal dominant polycystic kidney disease and metformin: Old knowledge and new insights on retarding progression of chronic kidney disease. <i>Medicinal Research Reviews</i> , 2022, 42, 629-640.	10.5	7
3	The gut microbiota as a biomarker in epilepsy. <i>Neurobiology of Disease</i> , 2022, 163, 105598.	4.4	15
4	Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis. <i>Drugs</i> , 2022, 82, 199-218.	10.9	47
5	Colchicine in Managing Skin Conditions: A Systematic Review. <i>Pharmaceutics</i> , 2022, 14, 294.	4.5	22
6	The microbiota-gut-brain axis and epilepsy from a multidisciplinary perspective: Clinical evidence and technological solutions for improvement of in vitro preclinical models. <i>Bioengineering and Translational Medicine</i> , 2022, 7, .	7.1	10
7	N-acetylcysteine aggravates seizures while improving depressive-like and cognitive impairment comorbidities in the WAG/Rij rat model of absence epilepsy. <i>Molecular Neurobiology</i> , 2022, , 1.	4.0	8
8	Status epilepticus in pregnancy: a literature review and a protocol proposal. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 301-312.	2.8	12
9	mGlu3 metabotropic glutamate receptors as a target for the treatment of absence epilepsy: preclinical and human genetics data. <i>Current Neuropharmacology</i> , 2022, 20, .	2.9	3
10	Targeting the MGBA with -biotics in epilepsy: New insights from preclinical and clinical studies. <i>Neurobiology of Disease</i> , 2022, 170, 105758.	4.4	6
11	Cathepsin-K is a potential cardiovascular risk biomarker in prevalent hemodialysis patients. <i>International Urology and Nephrology</i> , 2021, 53, 171-175.	1.4	5
12	Increased circulating Cathepsin-K levels reflect PTH control in chronic hemodialysis patients. <i>Journal of Nephrology</i> , 2021, 34, 451-458.	2.0	2
13	Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 99-110.	2.8	22
14	First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat. <i>Epilepsia</i> , 2021, 62, 529-541.	5.1	35
15	In Silico Strategy for Targeting the mTOR Kinase at Rapamycin Binding Site by Small Molecules. <i>Molecules</i> , 2021, 26, 1103.	3.8	9
16	Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program. <i>Frontiers in Pharmacology</i> , 2021, 12, 637801.	3.5	21
17	Appropriate use of generic and branded antiseizure medications in epilepsy: Updated recommendations from the Italian League Against Epilepsy (LICE). <i>Epilepsy and Behavior</i> , 2021, 116, 107804.	1.7	7
18	Pharmacokinetic drug interactions between antiseizure medications and drugs for comorbid diseases in children with epilepsy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 595-610.	3.3	0

#	ARTICLE	IF	CITATIONS
19	Assessing knowledge and attitudes toward epilepsy among schoolteachers and students: Implications for inclusion and safety in the educational system. PLoS ONE, 2021, 16, e0249681.	2.5	4
20	Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. Frontiers in Pharmacology, 2021, 12, 684638.	3.5	33
21	Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome. Frontiers in Neurology, 2021, 12, 673135.	2.4	23
22	Ixekizumab May Improve Renal Function in Psoriasis. Healthcare (Switzerland), 2021, 9, 543.	2.0	28
23	Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability. CNS Drugs, 2021, 35, 609-618.	5.9	34
24	Epidemiology and Outcomes of Status Epilepticus. International Journal of General Medicine, 2021, Volume 14, 2965-2973.	1.8	20
25	Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series. Medicine and Pharmacy Reports, 2021, 94, 289-297.	0.4	4
26	Therapeutic approach to difficult-to-treat typical absences and related epilepsy syndromes. Expert Review of Clinical Pharmacology, 2021, 14, 1-7.	3.1	5
27	Functional Gastrointestinal Disorders in Patients With Epilepsy: Reciprocal Influence and Impact on Seizure Occurrence. Frontiers in Neurology, 2021, 12, 705126.	2.4	8
28	Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights. International Journal of General Medicine, 2021, Volume 14, 5993-6000.	1.8	2
29	Increased efficacy of combining prebiotic and postbiotic in mouse models relevant to autism and depression. Neuropharmacology, 2021, 198, 108782.	4.1	33
30	Disease Modification in Epilepsy: Behavioural Accompaniments. Current Topics in Behavioral Neurosciences, 2021, , 145-167.	1.7	1
31	Critical Appraisal of Cenobamate as Adjunctive Treatment of Focal Seizures in Adults. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 3447-3457.	2.2	7
32	Renal denervation for resistant hypertension. The Cochrane Library, 2021, 2021, CD011499.	2.8	9
33	The risks of polypharmacy in ambulatory and home care patients affected with dementia: The PharE Study. Alzheimer's and Dementia, 2021, 17, e053117.	0.8	0
34	Clinically relevant drug interactions between statins and antidepressants. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 227-239.	1.5	24
35	A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report. Current Drug Safety, 2020, 15, 69-72.	0.6	7
36	Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats. Molecular Neurobiology, 2020, 57, 408-421.	4.0	53

#	ARTICLE	IF	CITATIONS
37	Modeling poststroke epilepsy and preclinical development of drugs for poststroke epilepsy. <i>Epilepsy and Behavior</i> , 2020, 104, 106472.	1.7	7
38	Butyrate prevents valproate-induced liver injury: In vitro and in vivo evidence. <i>FASEB Journal</i> , 2020, 34, 676-690.	0.5	37
39	IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG/Rij Rat Model of Absence Epilepsy. <i>Neurotherapeutics</i> , 2020, 17, 2004-2014.	4.4	24
40	Pain Modulation in WAG/Rij Epileptic Rats (A Genetic Model of Absence Epilepsy): Effects of Biological and Pharmacological Histone Deacetylase Inhibitors. <i>Frontiers in Pharmacology</i> , 2020, 11, 549191.	3.5	13
41	Pharmacokinetic considerations about antiseizure medications in the elderly. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 983-995.	3.3	9
42	An Open Retrospective Study of a Standardized Cannabidiol Based-Oil in Treatment-Resistant Epilepsy. <i>Cannabis and Cannabinoid Research</i> , 2020, , .	2.9	12
43	Metabolic Alterations Predispose to Seizure Development in High-Fat Diet-Treated Mice: the Role of Metformin. <i>Molecular Neurobiology</i> , 2020, 57, 4778-4789.	4.0	11
44	HDL (High-Density Lipoprotein) and ApoA-1 (Apolipoprotein A-1) Potentially Modulate Pancreatic $\beta$ -Cell Glucagon Secretion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2941-2952.	2.4	10
45	Management of status epilepticus in patients with liver or kidney disease: a narrative review. <i>Expert Review of Neurotherapeutics</i> , 2020, 21, 1-14.	2.8	4
46	P1417ALTERED CATHEPSIN-K LEVELS REFLECT SEVERITY OF MINERAL BONE DISEASE AND INFLAMMATION IN CHRONIC HEMODIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
47	P1422CATHEPSIN-K IS A POWERFUL DIAGNOSTIC BIOMARKER IN PARATHYROIDECTOMIZED DIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
48	The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a "real world" context: focus on temporal lobe epilepsy. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116903.	0.6	18
49	Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases. <i>Pharmacological Research</i> , 2020, 159, 105019.	7.1	11
50	Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. <i>Current Medical Research and Opinion</i> , 2020, 36, 1457-1463.	1.9	40
51	UbcH10 a Major Actor in Cancerogenesis and a Potential Tool for Diagnosis and Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2041.	4.1	17
52	Neural Modulation of the Primary Auditory Cortex by Intracortical Microstimulation with a Bio-Inspired Electronic System. <i>Bioengineering</i> , 2020, 7, 23.	3.5	6
53	Perampanel Confirms to Be Effective and Well-Tolerated as an Add-On Treatment in Patients With Brain Tumor-Related Epilepsy (PERADET Study). <i>Frontiers in Neurology</i> , 2020, 11, 592.	2.4	32
54	Metabolic and Cognitive Effects of Ranolazine in Type 2 Diabetes Mellitus: Data from an in vivo Model. <i>Nutrients</i> , 2020, 12, 382.	4.1	34

#	ARTICLE	IF	CITATIONS
55	Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1227.	2.4	14
56	Drug treatments in patients with cardiac diseases and epilepsy. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 37-49.	2.1	17
57	The potential role of interventions impacting on gut-microbiota in epilepsy. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 423-435.	3.1	25
58	Analgesic and Anti-Inflammatory Effects of Perampanel in Acute and Chronic Pain Models in Mice: Interaction With the Cannabinergic System. <i>Frontiers in Pharmacology</i> , 2020, 11, 620221.	3.5	10
59	Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. <i>PLoS ONE</i> , 2020, 15, e0241575.	2.5	38
60	A Volumetric Absorptive Microsampling Technique to Monitor Cannabidiol Levels in Epilepsy Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 582286.	3.5	7
61	Microbiota-gut brain axis involvement in neuropsychiatric disorders. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1037-1050.	2.8	116
62	Can we “seize” the gut microbiota to treat epilepsy?. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 750-764.	6.1	60
63	Immediate and controlled-release pregabalin for the treatment of epilepsy. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1167-1177.	2.8	6
64	P.07.29 ADVERSE DRUG REACTIONS DURING BIOLOGIC THERAPY IN INFLAMMATORY DISEASE: REAL LIFE DATA FROM THE PHARMACOVIGILANCE PROJECT IN THE CALABRIA REGION. <i>Digestive and Liver Disease</i> , 2019, 51, e235.	0.9	1
65	Gut microbiota and psychogenic non-epileptic seizures: i can feel it in the belly. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1165-1165.	2.8	2
66	Evaluation of the effects of liraglutide on the development of epilepsy and behavioural alterations in two animal models of epileptogenesis. <i>Brain Research Bulletin</i> , 2019, 153, 133-142.	3.0	24
67	Intestinal inflammation increases convulsant activity and reduces antiepileptic drug efficacy in a mouse model of epilepsy. <i>Scientific Reports</i> , 2019, 9, 13983.	3.3	51
68	Cognitive impairment in the WAG/Rij rat absence model is secondary to absence seizures and depressive-like behavior. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109652.	4.8	32
69	Hypertension, seizures, and epilepsy: a review on pathophysiology and management. <i>Neurological Sciences</i> , 2019, 40, 1775-1783.	1.9	51
70	Antiepileptogenic effects of Ethosuximide and Levetiracetam in WAG/Rij rats are only temporary. <i>Pharmacological Reports</i> , 2019, 71, 833-838.	3.3	18
71	Classical differentiation protocols upregulate the expression of the axon guidance genes PLXNA2 and SEMA3C in SH-SY5Y neuroblastoma cells. <i>Human Cell</i> , 2019, 32, 397-400.	2.7	5
72	Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 25-39.	1.8	6

#	ARTICLE	IF	CITATIONS
73	Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety. <i>European Journal of Medicinal Chemistry</i> , 2019, 163, 443-452.	5.5	31
74	Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: A case series and literature review. <i>Dermatologic Therapy</i> , 2019, 32, e12748.	1.7	23
75	Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. <i>Drugs of Today</i> , 2019, 55, 177.	1.1	30
76	WAG/Rij rat model: a resource for the pharmacology of epileptogenesis and related neurological/psychiatric comorbidities. <i>Neuroscience Research Notes</i> , 2019, 1, 18-34.	0.8	4
77	The role of AMPA receptors and their antagonists in status epilepticus. <i>Epilepsia</i> , 2018, 59, 1098-1108.	5.1	35
78	Intravenous carbamazepine for the treatment of epilepsy. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 743-747.	1.8	3
79	The effect of non-TNF-targeted biologics and small molecules on insulin resistance in inflammatory arthritis. <i>Autoimmunity Reviews</i> , 2018, 17, 399-404.	5.8	23
80	Brand-to-generic levetiracetam switching: a 4-year prospective observational real-life study. <i>European Journal of Neurology</i> , 2018, 25, 666-671.	3.3	17
81	Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. <i>Pharmacological Research</i> , 2018, 129, 274-294.	7.1	47
82	Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs. <i>Frontiers in Neurology</i> , 2018, 9, 1067.	2.4	60
83	Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP). <i>PLoS ONE</i> , 2018, 13, e0205134.	2.5	9
84	Pharmacology of epileptogenesis and related comorbidities in the WAG/Rij rat model of genetic absence epilepsy. <i>Journal of Neuroscience Methods</i> , 2018, 310, 54-62.	2.5	26
85	Perampanel in the treatment of status epilepticus: A systematic review of the literature. <i>Epilepsy and Behavior</i> , 2018, 86, 179-186.	1.7	42
86	Current treatment options for psoriatic arthritis: spotlight on abatacept. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1053-1059.	2.0	11
87	Metformin and Autoimmunity: A "New Deal" of an Old Drug. <i>Frontiers in Immunology</i> , 2018, 9, 1236.	4.8	131
88	Perampanel chronic treatment does not induce tolerance and decreases tolerance to clobazam in genetically epilepsy prone rats. <i>Epilepsy Research</i> , 2018, 146, 94-102.	1.6	3
89	Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis. <i>Current Pharmaceutical Design</i> , 2018, 23, 5546-5562.	1.9	36
90	Diagnostic Biomarkers of Epilepsy. <i>Current Pharmaceutical Biotechnology</i> , 2018, 19, 440-450.	1.6	20

#	ARTICLE	IF	CITATIONS
91	Serum Complement C3 and Type 2 Diabetes in Rheumatoid Arthritis: A Case-Control Study. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 215-221.	0.8	4
92	Insulin-Sensitizing Effects of Tumor Necrosis Factor Alpha Inhibitors in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 184-191.	0.8	11
93	Genetically epilepsy-prone rats (GEPRs) and DBA/2 mice: Two animal models of audiogenic reflex epilepsy for the evaluation of new generation AEDs. <i>Epilepsy and Behavior</i> , 2017, 71, 165-173.	1.7	35
94	Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects. <i>Behavioural Brain Research</i> , 2017, 321, 157-169.	2.2	77
95	Cerebral small vessel disease predisposes to temporal lobe epilepsy in spontaneously hypertensive rats. <i>Brain Research Bulletin</i> , 2017, 130, 245-250.	3.0	18
96	Kaposi's sarcoma after T-cell costimulation blockade with abatacept in rheumatoid arthritis: a case report. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 367-369.	1.5	6
97	Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 515-522.	2.4	17
98	Perampanel effects in the WAG/Rij rat model of epileptogenesis, absence epilepsy, and comorbid depressive-like behavior. <i>Epilepsia</i> , 2017, 58, 231-238.	5.1	48
99	Effects of eslicarbazepine acetate on lipid profile and sodium levels in patients with epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2017, 53, 1-3.	2.0	9
100	AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1751-1764.	1.8	54
101	The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1169-1178.	5.0	16
102	The potential role of cannabinoids in epilepsy treatment. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 1069-1079.	2.8	23
103	Activation of bottom-up and top-down auditory pathways by US sensors based interface. , 2017, , .		0
104	Methodological issues associated with clinical trials in epilepsy. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1103-1108.	3.1	7
105	Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2017, 7, 5346.	3.3	62
106	Complement C3 and fatty liver disease in Rheumatoid arthritis patients: a cross-sectional study. <i>European Journal of Clinical Investigation</i> , 2017, 47, 728-735.	3.4	26
107	Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG/Rij Rat Absence Epilepsy Model. <i>Neurotherapeutics</i> , 2017, 14, 1134-1147.	4.4	32
108	High Prevalence of Achilles Tendon Enthesopathic Changes in Patients with Type 2 Diabetes Without Peripheral Neuropathy. <i>Journal of the American Podiatric Medical Association</i> , 2017, 107, 99-105.	0.3	19

#	ARTICLE	IF	CITATIONS
109	Biomimetic Sonar for Electrical Activation of the Auditory Pathway. <i>Journal of Sensors</i> , 2017, 2017, 1-10.	1.1	7
110	Plantar fascia enthesopathy is highly prevalent in diabetic patients without peripheral neuropathy and correlates with retinopathy and impaired kidney function. <i>PLoS ONE</i> , 2017, 12, e0174529.	2.5	12
111	From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We?. <i>Current Pharmaceutical Design</i> , 2017, 22, 6426-6433.	1.9	8
112	Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients. <i>Current Drug Safety</i> , 2017, 12, 171-177.	0.6	17
113	The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 311-325.	1.4	9
114	Serum complement C3 strongly correlates with whole-body insulin sensitivity in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 18-23.	0.8	15
115	mTOR Signaling in Epilepsy and Epileptogenesis. , 2016, , 123-142.		4
116	The Anticonvulsant Activity of a Flavonoid-Rich Extract from Orange Juice Involves both NMDA and GABA-Benzodiazepine Receptor Complexes. <i>Molecules</i> , 2016, 21, 1261.	3.8	43
117	Complement C3 Is the Strongest Predictor of Whole-Body Insulin Sensitivity in Psoriatic Arthritis. <i>PLoS ONE</i> , 2016, 11, e0163464.	2.5	13
118	In vivo Evaluation of Selective Carbonic Anhydrase Inhibitors as Potential Anticonvulsant Agents. <i>ChemMedChem</i> , 2016, 11, 1812-1818.	3.2	36
119	Development and Validation of an HPLC-UV Assay for the Therapeutic Monitoring of the New Antiepileptic Drug Perampamil in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 744-750.	2.0	29
120	mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. <i>Pharmacological Research</i> , 2016, 107, 333-343.	7.1	144
121	Prevalence of Undiagnosed Diabetes in Rheumatoid Arthritis. <i>Medicine (United States)</i> , 2016, 95, e2552.	1.0	48
122	Lacosamide in patients with temporal lobe epilepsy: An observational multicentric open-label study. <i>Epilepsy and Behavior</i> , 2016, 58, 111-114.	1.7	12
123	Monitoring safety and use of old and new treatment options for type 2 diabetic patients: a two-year (2013-2016) analysis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 17-34.	2.4	6
124	Upholding WAG/Rij rats as a model of absence epileptogenesis: Hidden mechanisms and a new theory on seizure development. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 71, 388-408.	6.1	77
125	Pharmacokinetic-pharmacodynamic influence of N-palmitoylethanolamine, arachidonyl-2-chloroethylamide and WIN 55,212-2 on the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. <i>European Journal of Pharmacology</i> , 2016, 791, 523-534.	3.5	23
126	Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes. <i>Frontiers in Neuroendocrinology</i> , 2016, 42, 76-92.	5.2	51



#	ARTICLE	IF	CITATIONS
127	Tumour-associated macrophages correlate with microvascular bed extension in colorectal cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 1373-1380.	3.6	30
128	Retrospective analysis of type 2 diabetes prevalence in a systemic sclerosis cohort from southern Italy: Comment on "Reduced incidence of Type 1 diabetes and Type 2 diabetes in systemic sclerosis: A nationwide cohort study" by Tseng et al., <i>Joint Bone Spine</i> 2016;83:307-13. <i>Joint Bone Spine</i> , 2016, 83, 611-612.	1.6	15
129	Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence. <i>Pharmacological Research</i> , 2016, 113, 276-289.	7.1	48
130	Epilepsy in cerebrovascular diseases: Review of experimental and clinical data with meta-analysis of risk factors. <i>Epilepsia</i> , 2016, 57, 1205-1214.	5.1	122
131	Anticonvulsive Activity in Audiogenic DBA/2 Mice of 1,4-Benzodiazepines and 1,5-Benzodiazepines with Different Activities at Cerebellar Granule Cell GABAA Receptors. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 539-547.	2.3	4
132	Oral Metformin Ameliorates Bleomycin-Induced Skin Fibrosis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1892-1894.	0.7	23
133	Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment. <i>Cancer Letters</i> , 2016, 380, 216-226.	7.2	42
134	Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016, 107, 315-332.	7.1	30
135	Everolimus improves memory and learning while worsening depressive- and anxiety-like behavior in an animal model of depression. <i>Journal of Psychiatric Research</i> , 2016, 78, 1-10.	3.1	28
136	Genetics of reflex seizures and epilepsies in humans and animals. <i>Epilepsy Research</i> , 2016, 121, 47-54.	1.6	60
137	Structure-guided design of new indoles as negative allosteric modulators (NAMs) of N-methyl-D-aspartate receptor (NMDAR) containing GluN2B subunit. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 1513-1519.	3.0	9
138	Cannabidiol and epilepsy: Rationale and therapeutic potential. <i>Pharmacological Research</i> , 2016, 107, 85-92.	7.1	58
139	Valproic Acid Metabolism and its Consequences on Sexual Functions. <i>Current Drug Metabolism</i> , 2016, 17, 573-581.	1.2	40
140	When Nutraceuticals Reinforce Drugs Side Effects: A Case Report. <i>Current Drug Safety</i> , 2016, 11, 264-266.	0.6	17
141	Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5719.	4.3	11
142	Lymphocutaneous Sporotrichosis during Treatment with Anti-TNF-Alpha Monotherapy. <i>Case Reports in Rheumatology</i> , 2015, 2015, 1-3.	0.6	18
143	Profile of brivaracetam and its potential in the treatment of epilepsy. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 2967.	2.2	14
144	Rare and very rare adverse effects of clozapine. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1995.	2.2	71

#	ARTICLE	IF	CITATIONS
145	Recurrence of atrial fibrillation after switching from brand to generic atenolol. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2015, 6, 39.	0.4	5
146	Abatacept Improves Whole-Body Insulin Sensitivity in Rheumatoid Arthritis. <i>Medicine (United States)</i> , 2015, 94, e888.	1.0	61
147	Effects of chronic sodium alendronate on depression and anxiety in a menopausal experimental model. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 129, 65-71.	2.9	25
148	Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats. <i>Brain Research Bulletin</i> , 2015, 113, 1-7.	3.0	55
149	Epilepsy and Immune System: A Tour Around the Current Literature. , 2015, , 163-182.		0
150	Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the WAG/Rij rat model of absence epilepsy. <i>British Journal of Pharmacology</i> , 2015, 172, 3177-3188.	5.4	46
151	Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats. <i>Neurotherapeutics</i> , 2015, 12, 250-262.	4.4	22
152	Are big potassium-type Ca <sup>2+</sup> -activated potassium channels a viable target for the treatment of epilepsy?. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 911-926.	3.4	14
153	Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2355-2371.	1.8	33
154	Peroxisome proliferator-activated receptor alpha plays a crucial role in behavioral repetition and cognitive flexibility in mice. <i>Molecular Metabolism</i> , 2015, 4, 528-536.	6.5	48
155	Long-term betamethasone 21-phosphate disodium treatment has distinct effects in CD1 and DBA/2 mice on animal behavior accompanied by opposite effects on neurogenesis. <i>Behavioural Brain Research</i> , 2015, 278, 155-166.	2.2	8
156	Epilepsy associated with Leukoaraiosis mainly affects temporal lobe: a casual or causal relationship?. <i>Epilepsy Research</i> , 2015, 109, 1-8.	1.6	39
157	Statins and epilepsy: preclinical studies, clinical trials and statin-anticonvulsant drug interactions. <i>Current Drug Targets</i> , 2015, 16, 747-756.	2.1	37
158	Targeting Endothelial Progenitor Cells in Cancer as a Novel Biomarker and Anti-Angiogenic Therapy. <i>Current Stem Cell Research and Therapy</i> , 2015, 10, 181-187.	1.3	14
159	Targeting mast cells in gastric cancer with special reference to bone metastases. <i>World Journal of Gastroenterology</i> , 2015, 21, 10493.	3.3	20
160	A Comprehensive Safety Evaluation of Trabectedin and Drug-Drug Interactions of Trabectedin-Based Combinations. <i>BioDrugs</i> , 2014, 28, 499-511.	4.6	13
161	Targeting Î±-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 319-334.	3.4	40
162	Targeting Mast Cells Tryptase in Tumor Microenvironment: A Potential Antiangiogenic Strategy. <i>BioMed Research International</i> , 2014, 2014, 1-16.	1.9	52

#	ARTICLE	IF	CITATIONS
163	Synthesis, modelling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 1040-1048.	3.0	22
164	<i>Hypericum perforatum</i> : Pharmacokinetic, Mechanism of Action, Tolerability, and Clinical Drug-Drug Interactions. <i>Phytotherapy Research</i> , 2014, 28, 643-655.	5.8	138
165	Early molecular and behavioral response to lipopolysaccharide in the WAG/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK, AKT/mTOR pathways and neuroinflammatory cytokine release. <i>Brain, Behavior, and Immunity</i> , 2014, 42, 157-168.	4.1	84
166	Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG/Rij rats, a genetic animal model of absence epilepsy. <i>Epilepsia</i> , 2014, 55, 1284-1291.	5.1	54
167	Adherence to therapy and adverse drug reactions: is there a link?. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 41-55.	2.4	94
168	The mTOR signaling pathway and neuronal stem/progenitor cell proliferation in the hippocampus are altered during the development of absence epilepsy in a genetic animal model. <i>Neurological Sciences</i> , 2014, 35, 1793-1799.	1.9	25
169	Nonpsychotropic Plant Cannabinoids, Cannabidiol (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability. <i>ACS Chemical Neuroscience</i> , 2014, 5, 1131-1141.	3.5	301
170	Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 637-644.	1.8	13
171	Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 322-329.	4.4	57
172	Lack of efficacy during the switch from brand to generic allopurinol. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2013, 20, 540-542.	1.0	9
173	A review on antiepileptic drugs-dependent fatigue: Pathophysiological mechanisms and incidence. <i>European Journal of Pharmacology</i> , 2013, 718, 10-16.	3.5	32
174	Tryptase-positive mast cells and angiogenesis in keloids: a new possible post-surgical target for prevention. <i>Updates in Surgery</i> , 2013, 65, 53-57.	2.0	38
175	Huperzine A Restores Cortico-Hippocampal Functional Connectivity after Bilateral AMPA Lesion of the Nucleus Basalis of Meynert. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 833-846.	2.6	16
176	Efficacy and Safety of Off-Label Use of Fondaparinux in the Management of Heparin-Induced Thrombocytopenia with Thrombosis in an Elderly Woman. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 999-1002.	2.0	4
177	Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR- $\gamma$ receptor activation in a genetic model of absence epilepsy. <i>Neuropharmacology</i> , 2013, 69, 115-126.	4.1	91
178	mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. <i>Neuropharmacology</i> , 2013, 69, 25-36.	4.1	107
179	Pharmacodynamic potentiation of antiepileptic drugs' effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice. <i>Pharmacological Research</i> , 2013, 70, 1-12.	7.1	49
180	CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations. <i>Epilepsy Research</i> , 2013, 106, 74-82.	1.6	46

#	ARTICLE	IF	CITATIONS
181	Lamotrigine positively affects the development of psychiatric comorbidity in epileptic animals, while psychiatric comorbidity aggravates seizures. <i>Epilepsy and Behavior</i> , 2013, 28, 232-240.	1.7	30
182	Phthalates: European regulation, chemistry, pharmacokinetic and related toxicity. <i>Environmental Toxicology and Pharmacology</i> , 2013, 36, 88-96.	4.0	237
183	Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. <i>Neuropharmacology</i> , 2013, 64, 371-379.	4.1	72
184	Abatacept in psoriatic arthritis: Case report and short review. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S29-S32.	0.4	20
185	Safety and efficacy of generic drugs with respect to brand formulation. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S110-S114.	0.4	38
186	A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, 90.	0.4	5
187	Corticosteroid-related central nervous system side effects. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S94-S98.	0.4	158
188	Pharmacovigilance in Italy: An overview. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S20-S28.	0.4	67
189	Informatics applied to pharmacovigilance: Future perspectives. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, 43.	0.4	5
190	Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two "challenging" case reports. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S66-S72.	0.4	79
191	Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S55-S60.	0.4	12
192	Pharmacovigilance in Calabria (Italy): Local experiences resonate international relevance. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, 1.	0.4	2
193	Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis. <i>Advances in Pharmacological Sciences</i> , 2013, 2013, 1-8.	3.7	30
194	Measurements of rat brain activity originating from ultrasound waves in air. , 2013, , .		4
195	Mast Cell Positivity to Tryptase Correlates with Metastatic Lymph Nodes in Gastrointestinal Cancer Patients Treated Surgically. <i>Oncology</i> , 2013, 85, 111-116.	1.9	57
196	Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down&#39;s Syndrome. <i>Current Drug Safety</i> , 2013, 8, 69-71.	0.6	4
197	Efficacy and Safety of Bevacizumab in Glioblastomas. <i>Current Medicinal Chemistry</i> , 2012, 19, 972-981.	2.4	17
198	Immunohistochemical Analysis of the Ubiquitin-conjugating Enzyme UbcH10 in Lung Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2012, 60, 359-365.	2.5	33

#	ARTICLE	IF	CITATIONS
199	Synthesis and Biological Characterization of 3-Substituted 1 <i>H</i> -Indoles as Ligands of GluN2B-Containing <i>N</i> -Methyl-D-aspartate Receptors. Part 2. Journal of Medicinal Chemistry, 2012, 55, 10532-10539.	6.4	9
200	Protective activity of Î±-lactalbumin (ALAC), a whey protein rich in tryptophan, in rodent models of epileptogenesis. Neuroscience, 2012, 226, 282-288.	2.3	33
201	Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. Pharmacological Research, 2012, 65, 285-296.	7.1	37
202	New AMPA antagonists in epilepsy. Expert Opinion on Investigational Drugs, 2012, 21, 1371-1389.	4.1	52
203	The mTOR Signaling Pathway in the Brain: Focus on Epilepsy and Epileptogenesis. Molecular Neurobiology, 2012, 46, 662-681.	4.0	85
204	Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis. Journal of Research in Medical Sciences, 2012, 17, 872-5.	0.9	18
205	Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity. Behavioural Brain Research, 2011, 225, 373-376.	2.2	43
206	Synthesis and Biological Characterization of 3-Substituted-1 <i>H</i> -indoles as Ligands of GluN2B-Containing <i>N</i> -Methyl-D-aspartate Receptors. Journal of Medicinal Chemistry, 2011, 54, 8702-8706.	6.4	19
207	Macrophage Autophagy and Oxidative Stress: An Ultrastructural and Immunoelectron Microscopical Study. Oxidative Medicine and Cellular Longevity, 2011, 2011, 1-8.	4.0	19
208	New evidence for a critical role of elastin in calcification of native heart valves: immunohistochemical and ultrastructural study with literature review. Histopathology, 2011, 59, 504-513.	2.9	61
209	Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia, 2011, 52, 1341-1350.	5.1	71
210	Preclinical activity profile of Î±-lactalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy. Epilepsy Research, 2011, 95, 60-69.	1.6	41
211	Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. Epilepsia, 2010, 51, 1560-1569.	5.1	75
212	Synthesis and Structure-Active Relationship of 1-Aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Anticonvulsants. Chemical and Pharmaceutical Bulletin, 2010, 58, 1602-1605.	1.3	12
213	Jaw Osteonecrosis in Patients Treated with Bisphosphonates: An Ultrastructural Study. Ultrastructural Pathology, 2010, 34, 207-213.	0.9	20
214	Palmitoylethanolamide modulates pentobarbital-evoked hypnotic effect in mice. European Neuropsychopharmacology, 2010, 20, 195-206.	0.7	37
215	Altered distribution and function of A <sub>2A</sub> adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease. European Journal of Neuroscience, 2009, 30, 1023-1035.	2.6	43
216	Synthesis and evaluation of pharmacological profile of 1-aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1 <i>H</i> )-sulfonamides. Bioorganic and Medicinal Chemistry, 2009, 17, 3659-3664.	3.0	32

#	ARTICLE	IF	CITATIONS
217	Expression of tenascin-c and CD44 receptors in cardiac myxomas. <i>Cardiovascular Pathology</i> , 2009, 18, 173-177.	1.6	11
218	T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. <i>Neuropharmacology</i> , 2009, 56, 637-646.	4.1	29
219	Computational Studies to Discover a New NR2B/NMDA Receptor Antagonist and Evaluation of Pharmacological Profile. <i>ChemMedChem</i> , 2008, 3, 1539-1548.	3.2	37
220	Neuroactive steroids and GABA <sub>A</sub> receptor plasticity in the brain of the WAG/Rij rat, a model of absence epilepsy. <i>Journal of Neurochemistry</i> , 2008, 106, 2502-2514.	3.9	20
221	Effects of ethanol on the development of genetically determined epilepsies in rats. <i>International Journal of Developmental Neuroscience</i> , 2008, 26, 739-744.	1.6	14
222	Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive L-glutamate receptor antagonist in a genetic animal model of absence epilepsy. <i>Epilepsy and Behavior</i> , 2008, 13, 295-299.	1.7	20
223	The safety of clozapine in the elderly. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 525-538.	2.4	53
224	Apomorphine-induced neurodegeneration in Mongolian gerbil hippocampus. <i>Schizophrenia Research</i> , 2007, 95, 223-227.	2.0	2
225	Synthesis, resolution, stereochemistry, and molecular modeling of (R)- and (S)-2-acetyl-1-(4-chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline AMPAR antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 5417-5423.	3.0	27
226	Novel Potent Anticonvulsant Agent Containing a Tetrahydroisoquinoline Skeleton. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5618-5622.	6.4	32
227	Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. <i>Neuropharmacology</i> , 2006, 50, 1059-1071.	4.1	41
228	Effects of non-competitive AMPA receptor antagonists injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. <i>Neuropharmacology</i> , 2006, 51, 1058-1067.	4.1	33
229	Amino acid levels in some brain areas of inducible nitric oxide synthase knock out mouse (iNOS <sup>-/-</sup> ) before and after pentylenetetrazole kindling. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 85, 804-812.	2.9	24
230	Amino acid levels in some lethargic mouse brain areas before and after pentylenetetrazole kindling. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 81, 47-53.	2.9	5
231	AMPA Receptor Antagonists as Potential Anticonvulsant Drugs. <i>Current Topics in Medicinal Chemistry</i> , 2005, 5, 31-42.	2.1	70
232	Antiaabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats) Tj ETQq0 0 0 rgBT /Overlock 10 T	4.15	51
233	Melaena following Use of the Cholinesterase Inhibitor Rivastigmine. <i>Clinical Drug Investigation</i> , 2005, 25, 215-217.	2.2	16
234	Topiramate hyperpolarizes and modulates the slow poststimulus AHP of rat olfactory cortical neurones in vitro. <i>British Journal of Pharmacology</i> , 2004, 141, 285-301.	5.4	25

#	ARTICLE	IF	CITATIONS
235	Comparative anticonvulsant activity of N-acetyl-1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives in rodents. <i>Pharmacology Biochemistry and Behavior</i> , 2004, 77, 85-94.	2.9	41
236	Seizure susceptibility to various convulsant stimuli of knockout interleukin-6 mice. <i>Pharmacology Biochemistry and Behavior</i> , 2004, 77, 761-766.	2.9	62
237	Synthesis and anticonvulsant properties of tetrahydroisoquinoline derivatives. <i>Il Farmaco</i> , 2004, 59, 7-12.	0.9	25
238	Synthesis and anticonvulsant activity of N-3 substituted 2,3-benzodiazepines. <i>Il Farmaco</i> , 2004, 59, 353-358.	0.9	7
239	Effects of piracetam alone and in combination with antiepileptic drugs in rodent seizure models. <i>Journal of Neural Transmission</i> , 2004, 111, 1121-39.	2.8	8
240	Spinal myoclonus responsive to topiramate. <i>Movement Disorders</i> , 2004, 19, 1380-1381.	3.9	24
241	Synthesis and Anticonvulsant Properties of Tetrahydroisoquinoline Derivatives.. <i>ChemInform</i> , 2004, 35, no.	0.0	0
242	Synthesis and Anticonvulsant Activity of N-3 Substituted 2,3-Benzodiazepines.. <i>ChemInform</i> , 2004, 35, no.	0.0	0
243	Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. <i>Neuropharmacology</i> , 2004, 46, 865-878.	4.1	75
244	Anticonvulsant effects of carbenoxolone in genetically epilepsy prone rats (GEPRs). <i>Neuropharmacology</i> , 2004, 47, 1205-1216.	4.1	85
245	Seizure susceptibility to various convulsant stimuli in dystrophin-deficient mdx mice. <i>Neuroscience Research</i> , 2004, 50, 37-44.	1.9	34
246	Synthesis and anticonvulsant properties of 1,2,3,4-tetrahydroisoquinolin-1-ones. <i>Arkivoc</i> , 2004, 2004, 170-180.	0.5	12
247	Discovery of a Novel and Highly Potent Noncompetitive AMPA Receptor Antagonist. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 197-200.	6.4	80
248	Synthesis and Evaluation of Pharmacological Properties of Novel Annelated 2,3-Benzodiazepine Derivatives. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3758-3761.	6.4	48
249	Comparative anticonvulsant activity of some 2,3-benzodiazepine derivatives in rodents. <i>Pharmacology Biochemistry and Behavior</i> , 2003, 74, 595-602.	2.9	57
250	Synthesis and Anticonvulsant Activity of Novel Bicyclic Acidic Amino Acids. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3102-3108.	6.4	26